Atlas Trials

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

Clinical trial NCT05578846 · COMPLETED

Trial details

NCT number
NCT05578846
Sponsor
Alexion Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy Adult Participants
Start date
2022-10-13
Primary completion
2023-01-05
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.